Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-16

New preventative and therapeutic Hepatits C vaccines: from pre-clinical to phase I

Objective

With this project two major vaccine companies in Europe, IRBM (Merck) and Chiron, join their efforts with several European groups and one institution from Egypt to develop efficacious preventative and therapeutic Hepatitis C (HCV) vaccines. IRBM, in collaboration with CEINGE, has been working on a promising gene based HCV vaccine candidate using adenoviral vectors for delivery. This vaccine elicits potent CD4+ and CD8+ T cell responses and protects vaccinated chimpanzees from acute and chronic infection against challenge with a heterologous virus.

This vaccine candidate works by lowering viral replication, thus preventing chronic hepatitis. Chiron vaccine candidate consists in recombinant HCV glycoproteins, gpE1 and gpE2 associated to resemble to a pre-virion envelope structure. Protection against homologous and heterologous challenge, mediated by CD4+ T cell response and antibodies, was observed in experiments in chimpanzee using MF59 as adjuvant. This vaccine is already in phase 1 clinical trial.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

IP - Integrated Project

Coordinator

CEINGE- BIOTECNOLOGIE AVANZATE S.C.A R..L.
EU contribution
No data
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (14)

My booklet 0 0